Galapagos, in collaboration with MorphoSys, has started the IGUANA trial by screening the first patient of the trial.

IGUANA is a Phase II trial of MOR106 to treat patients with atopic dermatitis (AD).

The placebo controlled, double-blind trial is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of MOR106.

Under the trial, around 180 patients with moderate-to-severe AD will be treated over a 12-week period with one of three different doses of MOR106 or placebo using two different dosing regimens across various centres in Europe.

"Moderate-to-severe AD is a chronic, debilitating disease affecting millions of patients worldwide."

The trial will investigate dosing at two or four-week intervals over the 12-week treatment period, which will be followed by a 16-week observation period.

The primary objective of the trial is the evaluation of percentage change from baseline in Eczema Area and Severity Index (EASI) score at week 12.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MorphoSys chief development officer Dr Malte Peters said: “Moderate-to-severe AD is a chronic, debilitating disease affecting millions of patients worldwide.

“We see a clear unmet medical need for additional safe and efficacious treatment options and we are looking forward to further developing MOR106 for these patients in the Phase II trial we have now initiated together with our partner Galapagos.”

MorphoSys has used its Ylanthia antibody platform to develop MOR106, which is based on a target discovered by Galapagos.

MOR106 is an investigational antibody directed against IL-17C, a cytokine expressed preferentially in the skin and has been implicated in dermal inflammation.

IL-17C is also shown to be distinct from other members of the IL-17 cytokine family.

MorphoSys is yet to confirm the safety and efficacy of MOR106.